文献速递治疗药物监测与药物基因组学

医疗保健提供者心血管药物基因组学入门教程

An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare Providers.
PubMed 文献 · Clin Pharmacol Ther · 2023-06-12

本教程旨在为医疗保健提供者及学生提供心血管药物基因组学的入门教育,以克服临床实施中的教育不足、指南不一致和误解等障碍。教程分六步:理解基本概念、掌握基础知识、了解发布指南的机构、明确当前临床关注的心血管药物及证据、讨论示例病例、认识新兴领域。

要点

  • 药物基因组学可减少不良反应并提高心血管药物疗效。
  • 临床实施障碍包括教育不足、指南过时或不一致及误解。
  • 教程六步覆盖从基本概念到新兴领域的入门知识。

核心结论

  • 加强医疗保健提供者对心血管药物基因组学的教育有望改善这一主要发病和死亡原因相关疾病的结局。

研究设计与样本

  • 本文为入门教程,目标受众为任何有使用心血管药物或存在适应症患者的医疗保健提供者或学生。

关键数值与推荐

  • 教程分为6步:理解药物基因组学基本概念;获得心血管药物基因组学基础知识;了解发布心血管药物基因组学指南和建议的不同组织;了解当前临床上应关注的心血管药物/药物类别及支持证据;讨论一个心血管药物基因组学示例患者病例;认识心血管药物基因组学的新兴领域。

临床怎么用

  • 临床医生可按教程六步框架学习心血管药物基因组学,以应用于使用心血管药物的患者。

局限性

  • 当前心血管药物基因组学的临床建议可能过时、不完整或不一致,且医疗保健提供者中存在诸多误解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pharmacogenetics can improve clinical outcomes by reducing adverse drug effects and enhancing therapeutic efficacy for commonly used drugs that treat a wide range of cardiovascular diseases. One of the major barriers to the clinical implementation of cardiovascular pharmacogenetics is limited education on this field for current healthcare providers and students. The abundance of pharmacogenetic literature underscores its promise, but it can also be challenging to learn such a wealth of information. Moreover, current clinical recommendations for cardiovascular pharmacogenetics can be confusing because they are outdated, incomplete, or inconsistent. A myriad of misconceptions about the promise and feasibility of cardiovascular pharmacogenetics among healthcare providers also has halted clinical implementation. Therefore, the main goal of this tutorial is to provide introductory education on the use of cardiovascular pharmacogenetics in clinical practice. The target audience is any healthcare provider (or student) with patients that use or have indications for cardiovascular drugs. This tutorial is organized into the following 6 steps: (1) understand basic concepts in pharmacogenetics; (2) gain foundational knowledge of cardiovascular pharmacogenetics; (3) learn the different organizations that release cardiovascular pharmacogenetic guidelines and recommendations; (4) know the current cardiovascular drugs/drug classes to focus on clinically and the supporting evidence; (5) discuss an example patient case of cardiovascular pharmacogenetics; and (6) develop an appreciation for emerging areas in cardiovascular pharmacogenetics. Ultimately, improved education among healthcare providers on cardiovascular pharmacogenetics will lead to a greater understanding for its potential in improving outcomes for a leading cause of morbidity and mortality.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Oni-Orisan A, Tuteja S, Hoffecker G, et al. An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare Providers. Clin Pharmacol Ther. 2023. PMID: 37303270. doi:10.1002/cpt.2957

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。